Business
BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review
Following internal analysis and Data Monitoring Committee (DMC) feedback, the Company has elected to discontinue the BX004 Cystic Fibrosis (CF) Phase 2b trial BiomX continues to see potential in BX011, its phage program for Staphylococcus aureus (S. aureus) infections associated with diabetic foot infections (DFI). The Company is also implementing cost cutting measures, while evaluating strategic alternatives NESS ZIONA, Israel, Dec. 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE)
About this update from Biomx Inc.
[{"type":"image","alt":"BiomX Inc","displaySize":"","headline":null,"caption":"BiomX Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/edc14f9a8fd6cf813763ff819e8305ec"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/iDDZrA7bAG6OYNlatcV88w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/edc14f9a8fd6cf813763ff819e8305ec","width":300,"height":150}},"lazy":false},{"type":"text","content":"Following internal analysis and Data Monitoring Committee (DMC) feedback, the Company has elected to discontinue the BX004 Cystic Fibrosis (CF) Phase 2b trial","length":158,"tagName":"p"},{"type":"text","content":" BiomX continues to see potential in BX011, its phage program for Staphylococcus aureus (S. aureus) infections associated with diabetic foot infections (DFI). The Company is also implementing cost cutting measures, while evaluating strategic alternatives","length":253,"tagName":"p"},{"type":"text","content":"NESS ZIONA, Israel, Dec. 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced its discontinuation of the ongoing Phase 2b clinical trial of nebulized phage therapy BX004 in patients with CF associated with chronic Pseudomonas aeruginosa infections.","length":427,"tagName":"p"},{"type":"text","content":"The decision to discontinue the CF Phase 2b trial follows the Company’s previously announced safety review by the independent DMC on November 25, 2025. After assessing the DMC’s recommendations and conducting an internal analysis of unexpectedly high rates of adverse events, the Company has elected to discontinue the trial. Additionally, the Company plans to implement cost-cutting measures including a significant reduction in workforce while reviewing other strategic alternatives, aimed at maximizing shareholder value.","length":524,"tagName":"p"},{"type":"text","content":"“Our first priority is the improved treatment, health and safety of patients in the cystic fibrosis community, including those who enrolled in this trial. Patients living with cystic fibrosis continue to face significant challenges and require improved treatment optio...